1. Home
  2. Live Updates
  3. Andrewj armstrong

Live Breaking News & Updates on Andrewj armstrong

Stay informed with the latest breaking news from Andrewj armstrong on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Andrewj armstrong and stay connected to the pulse of your community

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone.

North-carolina , United-states , Chicago , Illinois , American , Andrewj-armstrong , Merck-sharp-dohme , American-society-of-clinical-oncology , Astrazeneca , Duke-cancer-institute-center , American-society

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone.

Chicago , Illinois , United-states , North-carolina , American , Andrewj-armstrong , Duke-cancer-institute-center , American-society-of-clinical-oncology , American-society , Clinical-oncology , Urologic-cancer

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

North-carolina , United-states , Andrewj-armstrong , Ashling-wahner , Facebook , Twitter , Duke-cancer-institute-in-durham , Linkedin , Duke-cancer-institute , Onclive-state , Science-summit , Apple-podcasts

Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC

Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Andrewj-armstrong , Duke-cancer-center , Duke-cancer-institute , D , Sc , Olaparib-plus-abiraterone-acetate , Patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer- , Propel-trial , Nct03732820 ,

New drug combo shows promise against prostate cancer in trials

In a phase 3 clinical trial by Pfizer, treatment with talazoparib and enzalutamide lowered the risk of prostate cancer progression or death by 37%.

Andrewj-armstrong , Coran-sternberg , Scottt-tagawa , Nicholas-zorko , Duke-cancer-institute-center , Pfizer , Masonic-cancer-center , University-of-minnesota , Urologic-cancers , Weill-cornell-medicine , Medical-news-today ,

TodayHeadline American In His 50s Develops New 'Uncontrollable' Irish Accent From Cancer

Breaking News Headlines Today

Irish-sea , Ireland-general- , Ireland , United-states , Americans , Irish , American , Stephen-colbert , Saoirse-ronan , Suzi-woltmann , Matthewk-labriola , Andrewj-armstrong

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Georgia , United-states , San-francisco , California , American , Andrewj-armstrong , Daniel-petrylak , Charles-schloss , Karim-fizazi , Ernesto-pablo-korbenfeld , Rustem-gafanov , Pawel-zalewski

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors


Researchers from City of Hope find only 30% of people with neuroendocrine tumors consider living longer to be their single top priority; 70% said addressing and overcoming pain, fatigue, or lack-of-function was more important than just prolonging life. JNCCN announces five new Associate Editors from Duke Cancer Institute, City of Hope, Mayo Clinic Cancer Center, University of Michigan...

United-states , Texas , F-marc-stewart , Mehran-yusuf , Andrewj-armstrong , Margaret-tempero , Facebook-nccnorg , Instagram-nccnorg , Daneng-li , Laurenp-wallner , Emily-bergsland , Anthonyj-olszanski

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

/PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National...

United-states , Texas , F-marc-stewart , Mehran-yusuf , Andrewj-armstrong , Margaret-tempero , Facebook-nccnorg , Instagram-nccnorg , Daneng-li , Laurenp-wallner , Emily-bergsland , Anthonyj-olszanski

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United-states , Texas , F-marc-stewart , Mehran-yusuf , Andrewj-armstrong , Margaret-tempero , Facebook-nccnorg , Instagram-nccnorg , Daneng-li , Laurenp-wallner , Emily-bergsland , Anthonyj-olszanski